In the literature, most studies proclaimed a negative impact of HER2 on the patients’ prognosis, as first described in breast carcinoma and which dramatically changed the standard therapy for numerous patients with the implementation of trastuzumab in the clinical routine [41, 42]. Here, ERBB2 is linked to breast carcinoma.